Tesamorelin vs GHRP-2

Tesamorelin and GHRP-2 are both research peptides studied across multiple applications, yet they operate through fundamentally different mechanisms. Tesamorelin, a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), stimulates endogenous GH and IGF-1 production via the pituitary. It is the only FDA-approved medication for reducing excess abdominal fat in HIV-infected adults with lipodystrophy (marketed as Egrifta), with a newer weekly-reconstitution formulation (Egrifta WR) approved in March 2025. In contrast, GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that acts through the ghrelin receptor (GHS-R) to induce potent, dose-dependent GH release. Approved in Japan as a diagnostic agent for GH deficiency, it has also been used clinically in GH-deficient children for 8–24 months with sustained efficacy. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy. by binding to GHRH receptors on pituitary somatotrophs. Phase 3 trials demonstrated significant visceral fat reduction over 26 weeks, with a generally well-tolerated safety profile. Notably, Egrifta WR, a new weekly-reconstitution formulation, received FDA approval in March 2025, potentially improving patient adherence. Research suggests that tesamorelin not only reduces visceral adipose tissue in HIV lipodystrophy but also increases skeletal muscle area and density, even in patients on integrase strand transfer inhibitor (INSTI)-based HIV regimens, which are associated with weight gain. These findings highlight its utility in managing metabolic complications in this population.

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that stimulates potent, dose-dependent GH release via the ghrelin receptor (GHS-R). It is considered more potent than GHRP-6 with less appetite stimulation. Approved in Japan as a diagnostic agent for GH deficiency (pralmorelin), it has been used clinically in GH-deficient children for 8-24 months with maintained efficacy on growth velocity. Clinical studies show a placebo-like safety profile at therapeutic doses.

Key claims: Potent growth hormone release; Diagnostic tool for GH deficiency; Sustained efficacy in long-term use.

Both peptides are studied for body composition, though their mechanisms and evidence bases differ. Tesamorelin is primarily researched for reducing visceral adipose tissue and improving skeletal muscle metrics in HIV-associated lipodystrophy, with robust phase 3 data. GHRP-2, while also investigated for body composition, is more commonly used in studies of GH secretion and diagnostic applications. Notably, both peptides share no additional unique research applications beyond body composition, suggesting that their primary overlap lies in GH-mediated effects on fat and muscle. Researchers may choose between them based on specific study goals: tesamorelin for targeted visceral fat reduction in metabolic disorders, or GHRP-2 for broader GH pulse modulation and diagnostic utility.

Tesamorelin: Common adverse events in clinical trials include injection site reactions (17%), arthralgia (13%), myalgia (6%), and peripheral edema (6%). Headache, nausea, and flu-like symptoms have also been reported. Importantly, tesamorelin may increase blood glucose levels, so monitoring is recommended in diabetic patients. GHRP-2: Well tolerated in clinical trials with a placebo-like safety profile at therapeutic ranges. It may increase appetite, though to a lesser extent than GHRP-6. Additionally, GHRP-2 can elevate cortisol and prolactin levels, but these effects are less pronounced than with GHRP-6. Researchers should consider these safety profiles when designing studies, particularly for long-term administration or in populations with metabolic comorbidities.